Skip to main content

News

News
04/17/2025
Jessica Garlewicz
These results support the continued development and clinical use of upadacitinib as a treatment strategy for patients with moderate-to-severe Crohn’s disease.
These results support the continued development and clinical use of upadacitinib as a treatment strategy for patients with moderate-to-severe Crohn’s disease.
These results support the...
04/17/2025
Advances in Inflammatory Bowel Disease Network
News
04/03/2025
Jessica Garlewicz
The findings suggest strong correlation between sweat-based readings and conventional serum and stool biomarkers, indicating potential for real-time disease monitoring.
The findings suggest strong correlation between sweat-based readings and conventional serum and stool biomarkers, indicating potential for real-time disease monitoring.
The findings suggest strong...
04/03/2025
Advances in Inflammatory Bowel Disease Network
News
04/03/2025
Jessica Garlewicz
Subcutaneous guselkumab showed significant clinical and endoscopic efficacy in patients with moderately to severely active Crohn’s disease.
Subcutaneous guselkumab showed significant clinical and endoscopic efficacy in patients with moderately to severely active Crohn’s disease.
Subcutaneous guselkumab showed...
04/03/2025
Advances in Inflammatory Bowel Disease Network
News
04/03/2025
Jessica Garlewicz
Patients with early response achieved higher rates of clinical remission and reductions in fatigue and impairment.
Patients with early response achieved higher rates of clinical remission and reductions in fatigue and impairment.
Patients with early response...
04/03/2025
Advances in Inflammatory Bowel Disease Network
News
04/03/2025
Jessica Garlewicz
A new study examined 792,409 hospitalizations for Crohn's disease, of which 26,229 (3.3%) involved patients with coexisting metabolic dysfunction-associated steatotic liver disease.
A new study examined 792,409 hospitalizations for Crohn's disease, of which 26,229 (3.3%) involved patients with coexisting metabolic dysfunction-associated steatotic liver disease.
A new study examined 792,409...
04/03/2025
Gastroenterology
News
04/01/2025
Jessica Garlewicz
The study highlights the utility of mucosal assessment in driving treatment optimization, even in asymptomatic patients.
The study highlights the utility of mucosal assessment in driving treatment optimization, even in asymptomatic patients.
The study highlights the utility...
04/01/2025
Advances in Inflammatory Bowel Disease Network
News
03/25/2025
Jessica Garlewicz
A multicenter prospective study has identified specific mucosa-associated microbiome changes that precede postoperative recurrence of Crohn’s disease.
A multicenter prospective study has identified specific mucosa-associated microbiome changes that precede postoperative recurrence of Crohn’s disease.
A multicenter prospective study...
03/25/2025
Advances in Inflammatory Bowel Disease Network
News
03/25/2025
Jessica Garlewicz
Despite significant progress in medical therapies for Crohn’s disease, a substantial number of patients still require surgical intervention.
Despite significant progress in medical therapies for Crohn’s disease, a substantial number of patients still require surgical intervention.
Despite significant progress in...
03/25/2025
Advances in Inflammatory Bowel Disease Network
FDA Alert
03/24/2025
Rebecca Mashaw
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last...
03/24/2025
Advances in Inflammatory Bowel Disease Network
News
03/19/2025
Rebecca Mashaw
Half of a small cohort of patients with Crohn’s disease of the pouch experienced clinical remission after 12 weeks of therapy with the IL-23 inhibitor.
Half of a small cohort of patients with Crohn’s disease of the pouch experienced clinical remission after 12 weeks of therapy with the IL-23 inhibitor.
Half of a small cohort of...
03/19/2025
Advances in Inflammatory Bowel Disease Network